These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 21303790

  • 1. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [Abstract] [Full Text] [Related]

  • 2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.
    Med Oncol; 2009 Dec; 26(1):32-7. PubMed ID: 18498064
    [Abstract] [Full Text] [Related]

  • 4. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer.
    Cao D, Guo CH, Liu JW, Yang X, Li Q.
    Tumori; 2015 Dec; 101(1):46-51. PubMed ID: 25702674
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K.
    Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [Abstract] [Full Text] [Related]

  • 7. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Tsutsumi S, Fujii T, Yamaguchi S, Suto T, Yajima R, Morita H, Kato T, Asao T, Kuwano H.
    Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
    Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D, First BEAT investigators.
    Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y.
    Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
    [Abstract] [Full Text] [Related]

  • 10. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y.
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [Abstract] [Full Text] [Related]

  • 11. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, Asaishi K, Miyamoto T, Higuchi K.
    Digestion; 2013 Aug; 87(1):59-64. PubMed ID: 23343971
    [Abstract] [Full Text] [Related]

  • 12. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [Abstract] [Full Text] [Related]

  • 13. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, RAISE Study Investigators.
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
    Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D.
    Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 16. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.
    J Clin Oncol; 2014 Jul 20; 32(21):2240-7. PubMed ID: 24687833
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T, Kato T, Yamazaki K, Yoshino T, Miyata Y, Esaki T, Moriwaki T, Boku N, Hyodo I.
    Cancer Chemother Pharmacol; 2015 Sep 20; 76(3):547-53. PubMed ID: 26198316
    [Abstract] [Full Text] [Related]

  • 18. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.
    Clin Colorectal Cancer; 2013 Dec 20; 12(4):239-47. PubMed ID: 24188685
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ueno M, Yamaguchi T.
    Asia Pac J Clin Oncol; 2014 Dec 20; 10(4):322-9. PubMed ID: 23915091
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M, Hoshino S, Noda N, Nakano M, Matsuo K, Yamauchi Y, Shinohara T, Tanaka S, Yamashita Y.
    Gan To Kagaku Ryoho; 2010 Jan 20; 37(1):83-8. PubMed ID: 20087037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.